Narrow your search

Library

KU Leuven (2)


Resource type

dissertation (2)


Language

English (2)


Year
From To Submit

2016 (2)

Listing 1 - 2 of 2
Sort by

Dissertation
NIHSS at baseline and after 24 ours as a predictor of outcome after ischemic stroke
Authors: --- ---
Year: 2016 Publisher: Leuven KU Leuven. Faculteit Geneeskunde

Loading...
Export citation

Choose an application

Bookmark

Abstract

Background: Multiple studies have focused on the baseline National Institutes of Health Stroke Scale (B-NIHSS) as a predictor of functional outcome after stroke. The change in NIHSS in the first 24h after stroke has been studied as a predictive variable for outcome, but the assessment of clinical improvement has been performed in various paradigms. In this study we intended to determine the accuracy of these different models. Methods: We included 369 patients in a retrospective study based on a database of 492 stroke patients. The NIHSS was calculated on admission and after 24 hours and the delta NIHSS, relative reduction (RR NIHSS) and major neurological improvement (MNI; NIHSS of 0-1 or≥8 point improvement at 24h) were calculated. The outcome at 90 days was measured by the Modified Rankin Score (mRS) and defined as good functional outcome (GFO): mRS of 0 to 2;and excellent functional outcome (EFO): mRS of 0 or 1. Independent predictors of GFO and EFO were identified by multivariate logistic regression. We performed a subgroup analysis after excluding minor stroke patients (NIHSS 0-5) since change in NIHSS at follow-up might be assessed more reliable in patients presenting with a severe deficit. Results: B-NIHSS was associated with both GFO (OR: 0.82; 95CI 0.78-0.86) and EFO (OR: 0.82; 95CI 0.77-0.86) with fair accuracy (AUC for GFO: 0.78, AUC for EFO: 0.75). Change in NIHSS after 24h was associated with GFO (OR:1.76; 95CI 1.07-2.97) and EFO (OR:2.19; 95CI 1.43-3.38) as calculated by the MNI without substantial accuracy (AUC for GFO: 0.57, AUC for EFO: 0.59).When excluding minor strokes B-NIHSS was associated with functional outcome (GFO OR:0.86; 95CI 0.79-0.93, EFO OR:0.88; 95CI 0.79-0.96) with fair to poor predictive value (AUC for GFO: 0.71, AUC for EFO: 0.66). Change in NIHSS had the most optimal accuracy (AUC for GFO: 0.67, AUC for EFO: 0.72)when determined by RR NIHSS which was associated with both GFO (OR: 6.4; 95CI 2.25-20.01) and EFO (OR:12.85; 95CI 3.69-51.55). Conclusion: B-NIHSS was associated with functional outcome with fair accuracy. Changes in NIHSS as assessed by three different definitions had less predictive value. The best predictive value of difference in NIHSS was obtained by MNI. When excluding all minor stroke this change in NIHSS had the most optimal accuracy if calculated by the RR NIHSS.

Keywords


Dissertation
Exploring the mechanism and therapeutic potential of the ephrin system in ALS

Loading...
Export citation

Choose an application

Bookmark

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a dramatic neurodegenerative disease due to its progressive character, the short survival of the patient and the enormous impact on his/her quality of life and that of his/her caretaker. Interestingly, ALS patients, even carrying the same mutation in SOD1, have great variations in clinical characteristics as age of onset, disease duration and severity of the disease. This indicates that ALS is a multifactorial disease influenced by modifying genes and environmental factors. Epha4 is such a genetic factor that modifies ALS both in animal models as well as in patients. We investigated the mechanism in which Epha4 is modifying the disease pathogenesis in ALS. We found that vulnerable motor neurons have high Epha4 expression and that Epha4 reduced the reinnervating capacity of motor neurons, possibly contributing to the higher vulnerability of Epha4 expressing motor neurons in ALS. Furthermore, deleting the Epha4 cytoplasmic domain did not affect disease onset and survival in the SOD1G93A mouse model indicating that Epha4 forward signaling in the Eph-bearing cell does not play a role in the modifying effect of Epha4 in ALS. We therefore suggest that the reverse pathway in the ephrin-bearing cell should be modified in order to alter ALS pathology. We studied ephrinb2 as a possible ligand for the Epha4-mediated effect in ALS. It was highly expressed in motor neurons and in reactive astrocytes. However, deletion of ephrinb2 enhanced disease rather than attenuating it. Interestingly, deleting ephrinb2 from the astrocytes impaired the blood brain barrier integrity which possibly contributed to the reduced disease duration and survival in the SOD1G93A mouse model. To inhibit Epha4 reverse signaling we developed Nanobodies targeting the EphA4 ligandbindingdomain. Nb 39 and Nb 53 were selective for EphA4, and had KD and IC50 values in the nanomolar range. Both Nanobodies were able to block the interaction of EphA4 with all ephrin ligands and they inhibited ephrin-induced phosphorylation. In conclusion, blocking the interaction of EphA4 and its ephrin ligands will be the most efficient way to block EphA4 reverse signaling and to develop a specific EphA4 antagonist.

Keywords

Listing 1 - 2 of 2
Sort by